Acadia Pharmaceuticals (ACAD) Free Cash Flow (2010 - 2026)

Acadia Pharmaceuticals' Free Cash Flow history runs 17 years deep, the most recent figure standing at $28.8 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 41.56% year-over-year to $28.8 million; the TTM figure through Mar 2026 stood at $113.6 million (down 23.48% YoY), while the FY2025 annual figure was $105.1 million, down 33.11% from the prior year.
• Free Cash Flow for Q1 2026 stood at $28.8 million, up from -$52.7 million in the prior quarter.
• The five-year high for Free Cash Flow was $85.4 million in Q4 2023, with the low at -$76.3 million in Q1 2022.
• The 5-year median for Free Cash Flow is $20.3 million (2025), against an average of $11.4 million.
• Peak annual rise in Free Cash Flow reached 457.97% in 2023, while the deepest fall reached 8009.35% in 2023.
• Acadia Pharmaceuticals' Free Cash Flow stood at -$23.9 million in 2022, then surged by 457.97% to $85.4 million in 2023, then slumped by 53.24% to $39.9 million in 2024, then slumped by 232.08% to -$52.7 million in 2025, then soared by 154.55% to $28.8 million in 2026.
• Business Quant data shows ACAD's Free Cash Flow at $28.8 million in Q1 2026, -$52.7 million in Q4 2025, and $73.9 million in Q3 2025.